Evidence map›Paper›PMID 42720969›Full record

ArticleHuman vaccines & immunotherapeutics2026

From vaccine availability to effective deployment: Closing the arboviral vaccine access gap.

Kok Keng Tee, Dongkui Mu, Binghui Wang, Xueshan Xia

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kok Keng TeeYunnan Provincial Key Laboratory of Cross-Border Infectious Diseases Control and Drug Innovation, School of Public Health, Kunming Medical University, Yunnan, China.ORCID 0000-0002-7923-5448
Dongkui MuYunnan Province Key Laboratory of Public Health and Biosafety, School of Public Health, Kunming Medical University, Yunnan, China.
Binghui WangYunnan Province Key Laboratory of Public Health and Biosafety, School of Public Health, Kunming Medical University, Yunnan, China.
Xueshan XiaYunnan Provincial Key Laboratory of Cross-Border Infectious Diseases Control and Drug Innovation, School of Public Health, Kunming Medical University, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mosquito-borne viral diseases are expanding globally, yet programmatic access to dengue and chikungunya vaccines remains limited or uneven in many high-risk settings. Using country-level classifications of regulatory approval and national immunization program inclusion, we identify substantial gaps between vaccine availability and areas at greatest epidemiological risk. The central challenge extends beyond vaccine feasibility to a multilayered vaccine-access gap spanning initial availability, sustained deployment and alignment with transmission risk. Current vaccine strategies remain reactive and insufficiently adapted to epidemiological patterns and health-system demands. Closing this gap will require preparedness-oriented frameworks that support timely introduction, durable coverage, and risk-adaptive deployment.

Indexed as

Arbovirus InfectionsHealth Services AccessibilityImmunization ProgramsViral VaccinesChikungunya FeverDengueGlobal HealthHumansMosquito-Borne DiseasesViral VaccinesArbovirus infectionschikungunya feverdengueglobal healthimmunization programsjapanese encephalitisvaccinationyellow fever

Identifiers

PMID42720969
PMCPMC13568584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.